IMMP / Immutep: Nipping At The Heels Of LAG3.Is It Impressive Enough?

Immutep Limited is a small cap biotech focusing on the development of eftilagimod alpha, a novel molecule that activates MHC class II molecules to enh more_horizontal

Baird, the investment bank, has initiated coverage on Immutep Ltd (ASX:IMM) (IMMP), a clinical-stage biotechnology company, with an "outperform" rati more_horizontal

While the idea of acquiring the best penny stocks under $3 may appeal to your inner contrarian, you need to first understand the risks. In most cases, more_horizontal

Immutep (IMMP) shares surge on encouraging initial data from a triple combination therapy study, INSIGHT-003, for non-small cell lung cancer. more_horizontal

A mid-stage study data shows that Immutep's (IMMP) lead candidate as a combination therapy in first-line NSCLC achieved better-than-expected overall s more_horizontal

Analysts and investors alike appear enamored with Immutep Ltd, whose earnings are growing; more of which could come from their latest product candidat more_horizontal

Immutep has been developing anti-LAG3 compounds for over a decade. Recent approval of the first such compound from BMY was a watershed event. more_horizontal

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play more_horizontal